Characterization of the Influence of Vildagliptin on Model-Assessed b-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia (Articolo in rivista)

Type
Label
  • Characterization of the Influence of Vildagliptin on Model-Assessed b-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia (Articolo in rivista) (literal)
Anno
  • 2008-01-01T00:00:00+01:00 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi
  • 10.1210/jc.2007-1639 (literal)
Alternative label
  • Mari A.; Scherbaum WA.; Nilsson PM.; Lalanne G.; Schweizer A.; Dunning BE.; Jauffret S.; Foley JE, (2008)
    Characterization of the Influence of Vildagliptin on Model-Assessed b-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia
    in The Journal of clinical endocrinology and metabolism
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Mari A.; Scherbaum WA.; Nilsson PM.; Lalanne G.; Schweizer A.; Dunning BE.; Jauffret S.; Foley JE, (literal)
Pagina inizio
  • 103 (literal)
Pagina fine
  • 109 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 93 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 1 (literal)
Note
  • ISI Web of Science (WOS) (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • 1: Institute of Biomedical Engineering (A.M.), National Research Council, I-35127 Padova, Italy / 2: Department of Endocrinology, Diabetes, and Rheumatology (W.A.S.), University Hospital Duesseldorf, D-40225 Duesseldorf, Germany / 3: University Hospital , 205 02, Malmö, Sweden / 4: Medical Group (G.L.), 40000 Mont de Marsan, France / 5: Novartis Pharmaceut, CH-4056 Basel, Switzerland / 6: PharmaWrite, Princeton, NJ 08540 USA / 7, 8: Novartis Pharmaceut Corp, E Hanover, NJ 07936 USA / (literal)
Titolo
  • Characterization of the Influence of Vildagliptin on Model-Assessed b-Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia (literal)
Abstract
  • Objective: This study was conducted to characterize the effects of vildagliptin on ?-cell function in patients with type 2 diabetes and mild hyperglycemia. Design: A 52-wk double-blind, randomized, parallel-group study comparing vildagliptin (50 mg every day) and placebo was conducted in 306 patients with mild hyperglycemia (glycosylated hemoglobin of 6.2-7.5%). Plasma glucose and C-peptide levels were measured during standard meal tests performed at baseline,wk24 and 52, and after 4-wk washout. Insulin secretory rate (ISR) was calculated by C-peptide deconvolution, and ?-cell function was quantified with a mathematical model that describes ISR as a function of absolute glucose levels (insulin secretory tone and glucose sensitivity), the glucose rate of change (rate sensitivity), and a potentiation factor. Results: Vildagliptin significantly increased fasting insulin secretory tone [between-group difference in adjusted mean change from baseline to wk 52 (AM?)??34.1 ? 9.5 pmol?min?1?m?2, P ? 0.001] glucose sensitivity (AM? ? ?20.7 ? 5.2 pmol?min?1?m?2?mM?1, P ? 0.001), and rate sensitivity (AM???163.6?67.0 pmol?m?2?mM?1, P?0.015), but total insulin secretion (ISR area under the curve at 0-2 h) and the potentiation factor excursion during meals were unchanged. These improvements in ?-cell function were accompanied by a decrease in the glucose area under the curve at 0-2 h (AM???1.7?0.5mM/h, P?0.002) and in glycosylated hemoglobin (AM???0.3? 0.1%, P ? 0.001). None of the effects of vildagliptin remained after 4-wk washout from study medication. Conclusions: Consistent with previous findings from shorter-term studies in patients with more severe hyperglycemia, in patients with mild hyperglycemia, improved ?-cell function is maintained throughout 52-wk treatment with vildagliptin and underlies a sustained improvement in glycemic control. However, no effects remain after washout. (literal)
Prodotto di
Autore CNR

Incoming links:


Prodotto
Autore CNR di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
data.CNR.it